NASH-treated microtissues have shown increased secretion of pro-inflammatory cytokines IL-6 and TNF-α (Fig. 3a) and pro-inflammatory chemokines MCP-1, MIP-1α, IL-8 and IP-10 (Fig. 3b). This evidence concerns the gene CCL3 and metabolic dysfunction-associated steatohepatitis.